Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 361-364 , September 2006

Classic and atypical myeloproliferative disorders

  • Ayalew Tefferi, MD (Professor of Hematology and Medicine Consultant)

      Affiliations

    • Corresponding Author InformationTel.: +1 507 284 3159; fax: +1 507 266 4972.

References 

  1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–375
  2. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  3. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Journal of National Cancer Institute. 1960;25:85
  4. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. British Journal of Haematology. 1994;87:746–754
  5. Fialkow PJ. Stem cell origin of human myeloid blood cell neoplasms. Verhandlungen der Deutschen Gesellschaft fur Pathologie. 1990;74:43–47
  6. Heisterkamp N, Stam K, Groffen J, et al. Structural organization of the bcr gene and its role in the Ph' translocation. Nature. 1985;315:758–761
  7. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233:212–214
  8. McLaughlin J, Chianese E, Witte ON. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proceedings of the National Academy of the Sciences of United Sciences of America. 1987;84:6558–6562
  9. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824–830
  10. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New England Journal of Medicine. 2003;348:1201–1214
  11. Bennett , Bennett JM. The myelodysplastic/myeloproliferative disorders: the interface. Hematology/Oncology Clinics of North America. 2003;17(5):1095–1100
  12. Tefferi A, Gilliland DG. JAK2 V617F in myeloproliferative disorders is not just another kinase. Cell Cycle. 2005; (in press).
  13. Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038–3045
  14. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307–316
  15. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. Journal of Clinical Investigation. 1993;92:1736–1744
  16. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proceedings of the National Academy of the Sciences of United Sciences of America. 1995;92:10560–10564
  17. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nature Genetics. 1996;12:312–314
  18. Xiao S, Nalabolu SR, Aster JC, et al. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nature Genetics. 1998;18:84–87
  19. Side LE, Emanuel PD, Taylor B, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood. 1998;92:267–272
  20. Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nature Genetics. 2003;34:148–150
  21. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061
  22. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005; in press.
  23. Kralovics R, Passamonti F, Buser AS, et al. A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. New England Journal of Medicine. 2005;352:1779–1790
  24. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397
  25. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in Polycythemia vera. Journal of Biological Chemistry 2005.
  26. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both ‘atypical’ myeloproliferative disorders and the myelodysplastic syndrome. Blood 2005.Blood First Edition Paper, prepublished online April 28, 2005; DOI 10.1182/blood-2005-03-1183.
  27. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005.Blood First Edition Paper, prepublished online May 26, 2005; DOI 10.1182/blood-2005-03-1320
  28. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clinic Proceedings. 2003;78:174–194
  29. Sandberg EM, Ma X, He K, et al. Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation. Journal of Medicinal Chemistry. 2005;48:2526–2533

PII: S1521-6926(05)00101-5

doi: 10.1016/j.beha.2005.07.014

Best Practice & Research Clinical Haematology
Volume 19, Issue 3 , Pages 361-364 , September 2006

Article Tools